Aurobindo Pharma has received warning letter from USFDA for OAI classification of Unit I, an API manufacturing facility in Hyderabad. This action follows the recent inspection of the unit by the USFDA in August 2021. The company will be engaging with the regulator and is fully committed in resolving this issue at the earliest. The company is also committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.